
PAVmed Inc
NASDAQ:PAVM

Operating Margin
PAVmed Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | Company | Market Cap |
Operating Margin |
||
---|---|---|---|---|---|
US |
![]() |
PAVmed Inc
NASDAQ:PAVM
|
9.9m USD |
-1 801%
|
|
US |
![]() |
Abbott Laboratories
NYSE:ABT
|
215.3B USD |
18%
|
|
US |
![]() |
Intuitive Surgical Inc
NASDAQ:ISRG
|
180.6B USD |
28%
|
|
US |
![]() |
Boston Scientific Corp
NYSE:BSX
|
159.3B USD |
19%
|
|
US |
![]() |
Stryker Corp
NYSE:SYK
|
151.9B USD |
22%
|
|
IE |
![]() |
Medtronic PLC
NYSE:MDT
|
117.2B USD |
20%
|
|
DE |
![]() |
Siemens Healthineers AG
XETRA:SHL
|
52.1B EUR |
14%
|
|
US |
![]() |
Becton Dickinson and Co
NYSE:BDX
|
52B USD |
13%
|
|
US |
![]() |
Edwards Lifesciences Corp
NYSE:EW
|
45.3B USD |
28%
|
|
US |
![]() |
IDEXX Laboratories Inc
NASDAQ:IDXX
|
43.3B USD |
29%
|
|
US |
![]() |
Resmed Inc
NYSE:RMD
|
39.8B USD |
32%
|
PAVmed Inc
Glance View
PAVmed, Inc. is a commercial-stage technology medical device company, which engages in the commercialization of medical technologies. The company is headquartered in New York City, New York and currently employs 89 full-time employees. The company went IPO on 2016-07-27. The firm has four operating divisions. GI Health division includes EsoGuard, EsoCheck and EsoCure. EsoGuard and EsoCheck have been developed to provide non-invasive, patient-friendly screening test for the early detection of adenocarcinoma of the esophagus (EAC) and Barrett's Esophagus (BE), including dysplasia and related pre-cursors to EAC in patients with chronic gastroesophageal reflux (GERD). EsoCure is in development as an Esophageal Ablation Device with the intent to allow a clinician to treat dysplastic BE before it can progress to EAC. Minimally Invasive Interventions division offers CarpX, a minimally invasive surgical device for carpal tunnel syndrome. Infusion Therapy division includes PortIO, which is an implantable, intraosseous vascular access device, and NextFlo, which is a disposable, infusion platform technology that includes intravenous infusion sets and disposable infusion pumps.

See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on PAVmed Inc's most recent financial statements, the company has Operating Margin of -1 801.1%.